A. Vranovský

发表

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

E. Kimby, A. Hagenbeek, M. van Glabbeke, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial.

D. de Jong, E. Noordijk, A. Stamatoullas, 2017, International journal of radiation oncology, biology, physics.

Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia

L. Dušek, R. Hájek, Z. Král, 2019, Journal of Cancer.

BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.

E. Kimby, A. Hagenbeek, M. van Glabbeke, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study

R. Foà, A. Ho, L. Arcaini, 2014, Annals of Hematology.

Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial.

A. Hagenbeek, R. Bouabdallah, F. Morschhauser, 2005 .

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

Max Wolf, Ivana Teodorovic, Randy D Gascoyne, 2006, Blood.

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

M. Beksac, M. Dimopoulos, B. Pégourié, 2019, The Lancet.

belinostat In Relapsed Or Refractory Peripheral T-cell Lymphoma (r/r Ptcl) Subtype Angioimmunoblastic T-cell Lymphoma (aitl): Results From The Pivotal Belief Trial : 153

P. Zinzani, S. Horwitz, O. O’Connor, 2013 .

Running title: Real-world effectiveness and safety of DVD in RRMM

Iveta, M. Mistrik, A. Vranovský, 2021 .

Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.

J. Lakota, A. Vranovský, V. Ballová, 2008, Neoplasma.

Acute vasculitis as a first manifestation of hairy cell leukemia.

P. Babál, A. Remková, E. Šteňová, 2007, European journal of internal medicine.

Acute myelomonocytic leukemia with t(1;18) in an adult patient.

A. Zámečníkova, A. Vranovský, J. Gyarfáš, 2002, Cancer genetics and cytogenetics.

Tandem autologous stem cell transplantation in multiple myeloma after high-dose chemotherapy with two separate collections: single institution experience.

J. Lakota, Ľ. Drgoňa, A. Vranovský, 2012, Neoplasma.

The MAXIMA Study: Safety of Rituximab (MabThera®) Maintenance Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma Who Have Responded to Induction Therapy.

R. Foà, L. Arcaini, M. Wenger, 2007 .

Coexistence of Philadelphia-positive Chronic Granulocytic Leukemia and Diffuse Large B-cell Lymphoma at Initial Diagnosis

P. Hlavčák, A. Vranovský, Adriana Zámečni´ková, 2002, Leukemia & lymphoma.

ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.

J. Raemaekers, G. Salles, D. de Jong, 2017, European journal of cancer.

Reply to U. Dührsen et al

E. Kimby, A. Hagenbeek, H. Holte, 2010 .

T001: FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial

A. Diepstra, A. Loft, A. Arens, 2022, HemaSphere.

Maintenance Rituximab Every 2 Months for 2 Years Is Effective and Well Tolerated In Patients with Follicular Lymphoma with Both Standard or Rapid Infusion: Updated Results From the Phase IIIb MAXIMA Study

R. Foà, A. Ho, L. Arcaini, 2010 .